APA (7th ed.) Citation

E, Z. d. L., C, C. C., B, R. C., B, S. S., M, L. O., CS, A. G., . . . MC, P. S. (2026). Three-year outcomes of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A real-world study. Medicina clinica, 166(8), 107448. https://doi.org/10.1016/j.medcli.2026.107448

Chicago Style (17th ed.) Citation

E, Zamarrón de Lucas, Crespo Catalán C, Romero Campos B, Sanz Sanjosé B, Longás Ouzzine M, Aponte Guevara CS, Álvarez-Sala Walther R, and Prados Sánchez MC. "Three-year Outcomes of Elexacaftor/tezacaftor/ivacaftor in Adults with Cystic Fibrosis: A Real-world Study." Medicina Clinica 166, no. 8 (2026): 107448. https://doi.org/10.1016/j.medcli.2026.107448.

MLA (9th ed.) Citation

E, Zamarrón de Lucas, et al. "Three-year Outcomes of Elexacaftor/tezacaftor/ivacaftor in Adults with Cystic Fibrosis: A Real-world Study." Medicina Clinica, vol. 166, no. 8, 2026, p. 107448, https://doi.org/10.1016/j.medcli.2026.107448.